SQSTM1/p62 as a prognostic indicator in pancancer and nasopharyngeal carcinoma.

IF 1.7 Q2 MULTIDISCIPLINARY SCIENCES

BMC Research Notes Pub Date : 2025-10-06 DOI:10.1186/s13104-025-07464-0

Li-Li Chen, Zong-Yao Zhang, Bo Wu, Mei-Zhen Lu

{"title":"SQSTM1/p62 as a prognostic indicator in pancancer and nasopharyngeal carcinoma.","authors":"Li-Li Chen, Zong-Yao Zhang, Bo Wu, Mei-Zhen Lu","doi":"10.1186/s13104-025-07464-0","DOIUrl":null,"url":null,"abstract":"Objective: This study evaluated SQSTM1/p62 expression patterns and its prognostic value across multiple cancers, with a focus on nasopharyngeal carcinoma (NPC).Results description: SQSTM1/p62 showed significantly higher mRNA and protein levels in tumors versus normal tissues across cancer types. High SQSTM1/p62 expression correlated with poorer OS and DSS in multiple cancers. Among 86 NPC patients (median follow-up 46.8 months), high SQSTM1/p62 expression (69.8% vs CNP 45% in controls, P = 0.036) independently predicted reduced DSS (HR = 4.51, 95% CI: 1.40-14.52). The unadjusted and multivariable-adjusted models consistently revealed a stable relationship between SQSTM1/p62 expression and patient prognosis. No significant interaction was observed between SQSTM1/p62 expression and age, TNM stage, or treatment methods (induction chemotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy). In summary, elevated SQSTM1/p62 expression correlates with poor clinical outcomes in pancancer analyses and serves as an independent prognostic factor for NPC.","PeriodicalId":9234,"journal":{"name":"BMC Research Notes","volume":"18 1","pages":"421"},"PeriodicalIF":1.7000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Research Notes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13104-025-07464-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study evaluated SQSTM1/p62 expression patterns and its prognostic value across multiple cancers, with a focus on nasopharyngeal carcinoma (NPC).

Results description: SQSTM1/p62 showed significantly higher mRNA and protein levels in tumors versus normal tissues across cancer types. High SQSTM1/p62 expression correlated with poorer OS and DSS in multiple cancers. Among 86 NPC patients (median follow-up 46.8 months), high SQSTM1/p62 expression (69.8% vs CNP 45% in controls, P = 0.036) independently predicted reduced DSS (HR = 4.51, 95% CI: 1.40-14.52). The unadjusted and multivariable-adjusted models consistently revealed a stable relationship between SQSTM1/p62 expression and patient prognosis. No significant interaction was observed between SQSTM1/p62 expression and age, TNM stage, or treatment methods (induction chemotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy). In summary, elevated SQSTM1/p62 expression correlates with poor clinical outcomes in pancancer analyses and serves as an independent prognostic factor for NPC.

查看原文本刊更多论文

SQSTM1/p62作为胰腺癌和鼻咽癌的预后指标。

目的：本研究评估SQSTM1/p62在多种癌症中的表达模式及其预后价值，重点研究鼻咽癌（NPC）。结果描述：SQSTM1/p62在不同癌症类型的肿瘤组织中的mRNA和蛋白水平明显高于正常组织。SQSTM1/p62高表达与多种癌症中较差的OS和DSS相关。在86例NPC患者中（中位随访46.8个月），高SQSTM1/p62表达（对照组中为69.8% vs 45%, P = 0.036）独立预测DSS降低（HR = 4.51, 95% CI: 1.40-14.52）。未经调整和多变量调整的模型一致显示SQSTM1/p62表达与患者预后之间存在稳定的关系。SQSTM1/p62表达与年龄、TNM分期或治疗方法（诱导化疗、同步放化疗、辅助化疗）无显著相互作用。总之，在癌症分析中，SQSTM1/p62表达升高与不良临床结果相关，并可作为鼻咽癌的独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Research Notes Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

3.60

自引率

0.00%

发文量

363

审稿时长

15 weeks

期刊介绍： BMC Research Notes publishes scientifically valid research outputs that cannot be considered as full research or methodology articles. We support the research community across all scientific and clinical disciplines by providing an open access forum for sharing data and useful information; this includes, but is not limited to, updates to previous work, additions to established methods, short publications, null results, research proposals and data management plans.